Pharmaceutical Danish drugmaker Lundbeck (LUND: DC) announced yesterday that Sycrest (asenapine) is being launched in the UK for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. This offers the first sublingual treatment choice for people with this serious and disabling disorder, affecting an estimated 623,000 patients in the UK, the company said. 16 January 2012